×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVO – novo nordisk a/s (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
05:52 am
nvo
Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide [Yahoo! Finance]
Neutral
Report
Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide [Yahoo! Finance]
12/4
11:58 am
nvo
Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer's, despite trial setback [MSNBC.com]
Low
Report
Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer's, despite trial setback [MSNBC.com]
12/4
10:58 am
nvo
Novo Nordisk A/S (NVO): A Bull Case Theory [Yahoo! Finance]
Low
Report
Novo Nordisk A/S (NVO): A Bull Case Theory [Yahoo! Finance]
12/4
09:00 am
nvo
4 stocks to watch on Thursday: NVO, PLTR, DG, PSKY [Seeking Alpha]
Low
Report
4 stocks to watch on Thursday: NVO, PLTR, DG, PSKY [Seeking Alpha]
12/4
06:34 am
nvo
Alzheimer's Clinical Trial Results, Sadly Running True To Form [Seeking Alpha]
Low
Report
Alzheimer's Clinical Trial Results, Sadly Running True To Form [Seeking Alpha]
12/3
09:58 pm
nvo
Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer’s, despite trial setback [MSNBC.com]
Low
Report
Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer’s, despite trial setback [MSNBC.com]
12/3
02:32 pm
nvo
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight [Yahoo! Finance]
Low
Report
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight [Yahoo! Finance]
12/3
01:42 pm
nvo
Novo Nordisk gears up for December Ozempic launch in India, sources say [Yahoo! Finance]
Low
Report
Novo Nordisk gears up for December Ozempic launch in India, sources say [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/25
08:19 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 25
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 25
11/24
10:19 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 24
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 24
11/17
03:36 pm
nvo
Form 6-K NOVO NORDISK A S For: Nov 17
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 17
11/14
10:13 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 14
Neutral
Report
Form 6-K NOVO NORDISK A S For: Nov 14
11/14
06:08 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 13
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 13
11/12
06:10 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 11
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 11
11/7
06:05 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 06
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 06
11/5
09:28 am
nvo
Form 6-K NOVO NORDISK A S For: Sep 30
Low
Report
Form 6-K NOVO NORDISK A S For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Form 6-K NOVO NORDISK A S For: Mar 16
6.0%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
TOP News Decliners
9/9
Form 6-K NOVO NORDISK A S For: Sep 09
-3.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: